Prevention of macrophage-related inflammatory diseases by allergina.
The oriental herbal combination allergina has been shown to inhibit allergic inflammation. In the present study, we demonstrate that the oral administration of allergina markedly inhibits the progression of inflammatory diseases, such as graft-versus-host diseases (in the allogeneic bone marrow transplantation and the parent-into-F1 transplantation models), collagen-induced arthritis and sheep red blood cell-induced delayed type hypersensitivity. The immunosuppressive activity of allergina in vivo appears to be associated, at least in part, with the inhibition of tumor necrosis factor-alpha production. In conclusion, our results suggest that allergina could be useful as a immunosuppressive agent for the treatment of macrophage-related inflammatory disease.
Han
Sang B
SB
Korea Research Institute of Bioscience and Biotechnology, 52 Oundong, Yusong, Taejon 305-333, Korea.
Lee
Chang W
CW
Park
Song K
SK
Yoon
Won K
WK
Moon
Jae S
JS
Lee
Ki H
KH
Kim
Hyung C
HC
Kim
Hwan M
HM
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000517:prevention & control; D024043:Collagen Type II / Q000008:administration & dosage*; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control; D007249:Inflammation / Q000188:drug therapy* / Q000473:pathology* / Q000517:prevention & control; D008070:Lipopolysaccharides / Q000009:adverse effects*; D008264:Macrophages / Q000473:pathology*; D008297:Male; D008518:Medicine, East Asian Traditional; D051379:Mice; D008811:Mice, Inbred DBA; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000187:drug effects*
C467830:Allergina; D000893:Anti-Inflammatory Agents; D024043:Collagen Type II; D008070:Lipopolysaccharides; D010936:Plant Extracts; D014409:Tumor Necrosis Factor-alpha